Safety of vaccine adjuvants: Focus on autoimmunity  by van der Laan, Jan Willem et al.
Vaccine 33 (2015) 1507–1514
Contents lists available at ScienceDirect
Vaccine
C
S
a
K
V
A
V
A
S
1
v
p
t
a
p
v
v
A
F
d
A
t
p
i
t
M
l
o
P
t
n
u
0
hj our na l ho me page: www.elsev ier .com/ locate /vacc ine
onference  report
afety of vaccine adjuvants: Focus on autoimmunity
 r  t  i  c  l  e  i  n  f  o
eywords:
accines
utoimmunity
accine adjuvants
nimal models
afety
a  b  s  t  r  a  c  t
Questions  have  been  recently  raised  regarding  the  safety  of vaccine  adjuvants,  particularly  in relation  to
autoimmunity  or autoimmune  disease(s)/disorder(s)  (AID).  The  International  Life Sciences Institute  (ILSI)
Health and  Environmental  Sciences  Institute  (HESI)  formed  a scientiﬁc  committee  and  convened  a  2-day
workshop,  consisting  of technical  experts  from  around  the  world  representing  academia,  government
regulatory  agencies,  and industry,  to investigate  and  openly  discuss  the  issues  around  adjuvant  safety  in
vaccines.  The  types  of adjuvants  considered  included  oil-in-water  emulsions  and  toll-like  receptor  (TLR)
agonists.  The  state  of  science  around  the  use  of animal  models  and  biomarkers  for the  evaluation  and
prediction  of  AID  were  also  discussed.  Following  extensive  literature  reviews  by the  HESI  committee,  and
presentations  by experts  at the  workshop,  several  key  points  were  identiﬁed,  including  the  value  of  animal
models used  to study  autoimmunity  and  AID  toward  studying  novel  vaccine  adjuvants;  whether  there  is
scientiﬁc  evidence  indicating  an  intrinsic  risk of  autoimmunity  and  AID with  adjuvants,  or  a  higher  risk
resulting  from  the  mechanism  of action;  and  if  there  is  compelling  clinical  data  linking  adjuvants  and  AID.
The  tripartite  group  of experts  concluded  that there  is  no compelling  evidence  supporting  the  association
of  vaccine  adjuvants  with  autoimmunity  signals.  Additionally,  it is recommended  that  future  research
on  the  potential  effects  of vaccine  adjuvants  on AID  should  consider  carefully  the  experimental  design
in  animal  models  particularly  if they  are  to be used  in any  risk  assessment,  as an  improper  design  and
model  could  result  in  misleading  information.  Finally,  studies  on the  mechanistic  aspects  and  potential
uvanbiomarkers  related  to adj
. Introduction
Vaccines play an important role in modern medicine in the pre-
ention of diseases. Safety is paramount, as vaccines are often given
rophylactically to healthy individuals. Most vaccines work under
he basic premise that the immune system becomes primed from
 possible future exposure upon vaccination, therefore, providing
rotection to an individual. In the case of highly puriﬁed subunit
accines that lack intrinsic innate immune activators (natural adju-
ants), various types of adjuvants are added during formulation to
Abbreviations: AID, autoimmune disorders; AF, adjuvant formulations;
SIA, autoimmune/inﬂammatory syndrome induced by adjuvants; CFA, complete
reund′s adjuvant; CIA, collagen-induced arthritis; DA, dark Agouti; DC, den-
ritic cells; EAE, experimental autoimmune encephalitis; EMA, European Medicines
gency; GWS, Gulf war  syndrome; HESI, Health and Environmental Sciences Insti-
ute; HLA, human leukocyte antigen; HPV, human papilloma virus; Hsp, heat shock
rotein; IBD, inﬂammatory bowel disease; IFA, incomplete Freund′s adjuvant; IFN,
nterferon; IL, interleukin; ILSI, International Life Sciences Institute; IMI, Innova-
ive  Medicines Initiative; MG,  myasthenia gravis; miRNA, micro-ribonucleic acid;
MF, macrophagic myofasciitis; MoA, mechanism of action; MPL, monophosphoryl
ipid A; mRNA, messenger ribonucleic acid; MS,  multiple sclerosis; NOD, non-
bese diabetic; O/W, oil-in-water; PAMPs, pathogen associated molecular patterns;
RRs, pattern recognition receptors; PY, person years; RA, rheumatoid arthri-
is; SjS, Sjögren′s syndrome; SLE, systemic lupus erythematosus; snRNPs, small
uclear ribonucleic particles; TLRs, toll-like receptors; Tregs, regulatory T cells; UTR,
ntranslated region; W/O, water-in-oil; WOW,  water-in-oil-in-water.
264-410X/$ – see front matter
ttp://dx.doi.org/10.1016/j.vaccine.2015.01.073ts  and  autoimmunity  phenomena  could  be  developed.
assist in a better education of the immune system, and thus, provide
better protection for any future insult. Developing adjuvants is
challenging, and adjuvants are under regulatory scrutiny as a result
of theoretical and reported safety concerns [1], which include
the risk of developing autoimmune diseases or AID, even if these
concerns are controversial due to confounding factors that may
attribute to the onset of AID. While research is constantly evolving
to enhance adjuvant design [2], the scope of this manuscript focuses
on two  types of adjuvants in marketed vaccines: oil-in-water
emulsions (e.g., squalene-based emulsions being used in inﬂuenza
vaccines) and toll-like receptor (TRL) agonists (e.g., monophospho-
ryl lipid A (MPL)/aluminum salt combination in Hepatitis B and
human papilloma virus (HPV) vaccines).
Possible safety concerns have arisen from studies in which
adjuvants have induced AID in various animal models and from
reports (primarily from one laboratory) that diverse compounds
with “adjuvant” activity could be associated with silicosis, Gulf
war syndrome (GWS), macrophagic myofasciitis (MMF), and
post-vaccination phenomena [3]. The recent cases of narcolepsy
observed during the 2009 pandemic inﬂuenza campaign with an
AS03-adjuvanted vaccine [4,5] have further heightened awareness.
Autoimmunity and AID are complex and result from a combina-
tion of genetic, hormonal and/or environmental triggers [6]; thus,
attributing causality is not easy. Certain adjuvants have speciﬁc
receptor targets that strongly stimulate the immune system via pat-
tern recognition receptors (PRRs), including TLRs, and stimulating
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uch targets could theoretically increase the risk of initiation or
rogression of systemic AID [7].
As a consequence, questions are raised that need to be consid-
red, such as: is the induction of AID in experimental settings due
o exaggerated immune activation through the use of adjuvants?
hat is the relevance of animal data to humans? Do adjuvants
nduce autoimmunity and/or AID as a result of an exaggerated effect
n a clinical setting, i.e., can some autoimmune diseases inherently
e associated with adjuvants?
To address these questions, the International Life Sciences Insti-
ute (ILSI) Health and Environmental Sciences Institute (HESI)
ormed a multi-sector, international scientiﬁc committee, the Vac-
ines and Adjuvants Safety Project Committee (HESI committee),
n 2011 to conduct a multi-faceted approach to assess the state of
he science on adjuvants and AID. This approach included a sur-
ey of the current experimental and epidemiological literature and
he convening of a Workshop on Adjuvants and Vaccines: Focus
n Autoimmunity on October 18–19, 2012 in Amsterdam, The
etherlands. The workshop brought together 35 international sci-
ntists from academia, industry, and government to deliberate the
elationship between adjuvants and vaccine safety [8].
. Interplay between vaccines and the immune system is a
elicate balanceThe immune system is designed to recognize dangerous vs. safe
ntigens. It is a delicate system with many components that involve
ells and signals that “turn on” and those that are responsible for
turning off” a response once the insult has cleared. Vaccines, and
ig. 1. Current understanding of MF59® adjuvant activity. (A) MF59 adjuvant in combin
esident monocytes, macrophages, and dendritic cells are activated and respond by ind
igniﬁcant inﬂux of phagocytic cells that take up the antigen and differentiate into ant
ransport of antigen to the lymph nodes, where the immune response is triggered thro
mmature dendritic cell; mDC: Monocytic dendritic cell. Reprinted from Vaccine, 30, O′Ha
nnately attractive adjuvant formulation, 4341-8, copyright (2012), with permission from33 (2015) 1507–1514
with the help of adjuvants, are designed to utilize this delicate bal-
ance in the immune system to drive protection for a host from
viral, bacterial, or fungal infection. The physical–chemical prop-
erties of adjuvants and how they interact with the antigen(s), are
important in deﬁning how the immune system may  respond, albeit
to promote a protective humoral response or a response biased
toward cell-mediated immunity. Antigen selection and adjuvant
design are no longer empirical, and new generation adjuvants can
speciﬁcally direct the desired immune responses [9]. Adjuvants,
like oil-in-water or TLR agonists are designed to promote a more
robust and/or tuned immune response to the antigen in the vac-
cine formulation in order to provide better protection. Oil-based
emulsion adjuvants include MF59 (squalene), ASO3 (squalene, -
tocopherol), and Montanide (Seppic; various metabolizable and
mineral oils). There are abundant animal study data on one exam-
ple of this class of adjuvants, MF59 [10]. These data illustrate
the complex molecular mechanisms associated with this class of
adjuvants as illustrated in Fig. 1. MF59 both increases the uptake
of antigens by antigen presenting cells (e.g., dendritic cells) and
activates the innate immune response locally, providing the criti-
cal immunologically competent micro-environment for productive
generation of B and T cell immunity. Importantly, MF59 does
not activate the immune system systemically, and does not lead
to detectable polyclonal immune activation even in the draining
lymph node. Thus, a critical aspect of safe and highly effective
adjuvants is one that can act locally at the site of injection in
order to limit systemic effects, and therefore enhance its prob-
ability to be safe while still in an active form from an immune
perspective.
ation with a vaccine antigen is injected into the muscle. (B) In the muscle, tissue-
ucing a mixture of chemokines (CCL2, CXCL8, CCL4, and CCL5), which results in a
igen-presenting cells (dendritic cells). These cells are responsible for the efﬁcient
ugh the activation of T and B cells and antibody production. Ab: Antibody; iDC:
gan DT, Ott GS, De Gregorio E,and Seubert A. The mechanism of action of MF59–an
 Elsevier [10].
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TLRs, for their part, are a family of PRRs expressed predomi-
antly by cells of the innate immune system that sense “danger”
y recognizing speciﬁc exogenous pathogen associated molecular
atterns (PAMPs) found on invading organisms, e.g., bacteria and
iruses. Activation of TLRs drives the maturation of dendritic cells
DC) and other antigen presenting cells (APCs), activates naïve T
ells, and increases immunogenicity. Many vaccines naturally con-
ain PAMPs: for example, attenuated and killed vaccines contain
iral or bacterial nucleic acids that activate various surface (Fig. 2)
nd/or endosomal (Fig. 3) TLRs [11], whole cell Gram-negative
acteria vaccine that express LPS (TLR4), and Gram-positive whole
ell bacteria vaccine that express peptidoglycan (TLR2). This acti-
ation, either to surface or intracellular TLRs, would promote
nﬂammatory cytokine production, which in theory could also be
uggested as playing a pathogenic role in AID.
With an increased understanding of the immune system and
accines, adjuvant formulations (AF) have been developed that
ombine different types of adjuvants into speciﬁc formulations
hat can localize and provide staggered antigen release (Signal
) as well as provide a nonself and/or danger signal (Signal
). Signal 1-facilitating adjuvants (mostly nonmicrobial) bene-
cially modify antigen-associated characteristics and delivery.
ignal 2-facilitating adjuvants (“stranger”, “danger”, or endogenous
mmunopotentiators) beneﬁcially modify host immune respon-
iveness during recognition of antigen by adaptive immune cells.
iven the potential interplay between these adjuvants and the
atient′s immune system, these systems are being studied to
ssess both efﬁcacy and risk. For example, the AS04-adjuvanted
PV-16/HPV-18 vaccine (Cervarix®), consists of a combination of
LR agonists, MPL, and aluminum salts. Cervarix® can be used
o exemplify the mechanism of action (MoA) for AS04, and how
t contributes to immunogenicity and efﬁcacy in humans. MoA
ata showed that AS04 promotes an antibody response strictly
ependent on spatial and temporal co-localization with the antigen
12]. It induces local nuclear factor kappa-light-chain-enhancer of
ig. 2. PAMP recognition by cell surface TLRs and the subsequent signaling cascade. Repr
kira  S. The role of pattern-recognition receptors in innate immunity: update on toll-like33 (2015) 1507–1514 1509
activated B cells (NF-B) activity and cytokine production within a
few hours and days after immunization, respectively. This results in
an increased number of activated antigen loaded dendritic cells and
monocytes in the draining lymph node, which further increased the
activation of antigen-speciﬁc T cells. These AS04-induced innate
responses were primarily caused by MPL, whereas the aluminum
salt prolonged the cytokine responses to MPL  overall leading to an
enhanced adaptive immune response to the antigens. In the case
of Cervarix®, an integrated analysis of over 68,000 adolescents and
young adults who received this vaccine platform demonstrated that
there were low rates of autoimmune disorders, with no evidence
of an increase in relative risk [12]. This study is a strong and pow-
erful indication that formulated TLR4 agonists have, very likely, no
impact on autoimmune disorders onset in humans after a 5-year
follow-up at least.
3. AID is complex with many targets and contributing
factors
All the various components of the immune system working in
tandem can, however, malfunction. In case this system misdirects a
response against self (by molecular mimicry or by blocking or coun-
teracting peripheral tolerance), it can give rise to autoimmunity,
which can be recognized through the presence of autoantibodies
or autoreactive T cells. It can occur in both “healthy” individuals
and in various disease states, and if it progresses from benign to
pathogenic with the loss of control by the host, then AID is observed
[13].
There have been over 80 different AID identiﬁed where the
immune system inappropriately attacks itself via autoreactive anti-
bodies or T cells, leading to destruction of tissues, abnormal growth
of organ(s), and/or changes in function. AID can be either organ
speciﬁc or systemic. Typical targets are blood vessels, connective
tissues, endocrine glands, joints and muscles, red blood cells, or
the skin. Common AID include systemic lupus erythematosus (SLE),
inted by permission from Macmillan Publishers Ltd: Nature Immunology (Kawai T,
 receptors. Nat Immunol, 11, 373–84), copyright (2010) [11].
1510 Conference report / Vaccine 33 (2015) 1507–1514
Fig. 3. PAMP recognition by intracellular TLRs and the subsequent signaling cascade. Reprinted by permission from Macmillan Publishers Ltd: Nature Immunology (Kawai T,
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ype I (insulin-dependent) diabetes, Addison′s disease, gluten-
ensitive enteropathy (celiac disease), dermatomyositis, Grave′s
isease, Hashimoto′s thyroiditis, multiple sclerosis (MS), myas-
henia gravis (MG), pernicious anemia, reactive and rheumatoid
rthritis (RA), and Sjögren′s syndrome (SjS). There have been a
mall number of cases that have linked infectious diseases to AID
e.g., reactive arthritis, rheumatic fever, or vasculitis associated
ith hepatitis B virus infection). Background rates of AID are very
ow ranging from 0.8/100,000 person-years (PY) for autoimmune
emolytic anemia to 54.1/100,000 PY for thyroiditis–and vary by
re-speciﬁed criteria that included age, race, and gender [14]. For
etailed classiﬁcation of autoimmune etiology see Rose and Bona
15].
The risk of developing AID is complex, and multiple factors
ncluding genetic predisposition, environmental, and immune dys-
egulation may  all play a role. These complex interrelationships
hould be considered when evaluating the potential causal rela-
ionships between autoimmune phenomena and/or disease and an
djuvant exposure.
Although association between vaccine adjuvant exposures and
IDs have been asserted in the literature and general media,
here is no clear evidence of a causal association. For example,
ith some vaccinations, the most frequent assertions of AID (e.g.,
uillain–Barré syndrome) relates to a relatively small number of
atients, and in controlled studies of autoimmunity post immu-
ization, there has been no evidence of an association found. For receptors. Nat Immunol, 11, 373–84), copyright (2010) [11].
example, no evidence linking viral vaccines with type 1 diabetes,
MS or inﬂammatory bowel disease (IBD) can be found [16].
4. Challenges in translation of preclinical models
4.1. Animal models
Animal models are an exploratory research tool, but is it possible
to use them in a relevant manner to elucidate causes and mecha-
nisms of AID? Could data from these models be used to support
critical safety and efﬁcacy assessments or drug/vaccine develop-
ment decisions? Commonly studied animal models for evaluation
of AID include experimental allergic encephalitis (EAE) for MS,
collagen-induced arthritis (CIA) for RA, the (NZBxNZW) F1 mouse
for SLE, and the non-obese diabetic (NOD) mouse for type I diabetes
and SjS. There are also spontaneous (limited data) and inducible
(CIA and EAE) nonhuman primate autoimmunity models. Animal
models may  provide insight into disease pathology because of cer-
tain physiological similarities with humans and their brief life span
may  allow the full disease onset to be studied within a short period
of time. These animal models can be divided into two categories:
models that are naturally susceptible to autoimmune disease (e.g.,
NOD) and those where AID is induced (e.g., CIA). The former allows
for the testing of how adjuvants can accelerate or delay the onset
of disease, while the later may  test an adjuvant′s ability to interfere
with the induction/exacerbation mechanisms of AID. However, no
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nimal model can replicate the spectrum of a single human dis-
ase, and although helpful to study AID mechanisms, they may  not
e applicable to evaluate vaccine adjuvant-induced autoimmunity
17]. Immunological responses in animal models vary according to
enetic inﬂuence and species-speciﬁc responses may  be an obsta-
le in translating preclinical animal studies. In the case of adjuvant
afety, it is critical to acknowledge important differences in dose,
ormulation, and route of administration between the products
sed to induce experimental autoimmune disorders in animals and
he parallel scenarios for human exposure to adjuvants used in
arketed vaccines.
The literature review by the HESI committee identiﬁed
undreds of papers showing various oil-based adjuvants that have
een administered in animal models with either overt autoim-
une phenotypes, or a propensity to develop AID [18,19]. While
hese models were generally established to look at the mechanisms
ehind autoimmunity and AID, rather than looking for any speciﬁc
djuvant effect, they do provide an indication of key experimental
actors linked to adjuvant administration that could inﬂuence the
otential for an autoimmune response. The autoimmunity models
eviewed, e.g., arthritis, lupus, thyroiditis, glomerulonephritis, mul-
iple sclerosis, diabetes, and pancreatitis, were developed primarily
n small animals.
.2. Formulations
Furthermore, differences in antigen release in vitro, immuno-
enicity in vivo, and tolerability between water-in-oil (w/o),
ater-in-oil-in-water (wow), and oil-in-water (o/w) emulsions are
llustrated with examples from the literature [20]. Antigen release
n vitro and immunogenicity in vivo correlated with o/w emulsions
aving the quickest in vitro release and the lowest immunogenic-
ty, followed by wow, and w/o having the slowest antigen release
nd the highest immunogenicity. The oil used, droplet size, and
atio of oil to water, all affected the immunogenicity of antigen and
he local tolerability. Considering the impact of physical/chemical
roperties of the various emulsion adjuvants on immunogenicity
nd tolerability, the human relevance of studies using pure squa-
ene oil in rodents [21,22] draws into question as to whether the
ame conclusions seen in animals can be applied to humans.
.3. Protocols
A closer look at protocols used to induce autoimmunity or
ID in the animal models showed large doses were administered
ften via routes not relevant to human administration. Plus, in
any cases, self-proteins are administered together with adju-
ants in order to induce autoimmunity or AID [23]. Oil-in-water
djuvants in humans are dosed by the intramuscular route in a
olume of 0.5 mL  per vaccine dose. The oil and surfactant com-
onents of the adjuvants are in the range of 10–13 mg  of the oil
omponent (metabolizable squalene), and 2.5–5 mg  of the surfac-
ant components [24–26], per dose to humans with body weights
rom ∼4 kg (infant) to 60 kg (adult). In rodent studies with com-
lete Freund′s (CFA) and incomplete Freund′s (IFA) adjuvants,
ristane (tetramethylpentadecane), mineral oils, and hydrocarbons
all non- or slowly metabolized), animals were dosed via intrader-
al  injection or into the peritoneal cavity. In studies that showed
ristane, IFA, and squalene oil induced arthritis in rats [21,22,27]
nd lupus associated autoantibodies in mice [28], with associated
ytokines [29,30], the dose volumes ranged from 0.1 to 0.5 mL  in
ice and rats. For example, on a body weight basis, a dose of
.5 mL  to a 0.03 kg mouse is equivalent to injecting 200 mL  into
 60 kg human. The differences in oils, formulations, dose levels,
nd route of administration, together with known and potential33 (2015) 1507–1514 1511
species differences in immune responses, means caution is needed
in extrapolating the results in these animal studies to humans.
4.4. Focus on translation for TLR agonist adjuvants
Published studies on the link between TLR and AID illustrate
the complexity of translating preclinical AID-related animal data to
the patient. For many AID, there are conﬂicting data regarding the
role (and identity) of TLRs, and data either indicating an exacerba-
tion or amelioration of disease. Table 1 provides an overview of the
various TLRs that may  be involved in AID, and the similarities and
differences between human and in animals. The variability between
humans and animals is likely a reﬂection of the species-speciﬁc
differences of TLRs in tissue and cellular distribution, expression,
ligand recognition, and subsequent cascade pathways. From a pre-
clinical perspective, studies often used either transgenic or induced
disease models, including TLR−/− or myeloid differentiation pri-
mary response gene 88 (MyD88)−/− knockout animals [7,31–33].
Mouse gene knock-out studies show that some TLRs are essential
for the development of autoimmunity in prone strains, although
not necessarily causative. Likewise, administration of TLR ago-
nists to animal models can exacerbate disease (e.g., imiquimod
TLR7 can induce diabetes in NOD mice) [34]. However, data are
inconsistent, and there are many examples where TLR agonists do
not induce or exacerbate autoimmunity but can protect against
autoimmunity. Few papers have addressed the differences in TLR
distribution between animals and humans. The studies reviewed
did not address the role that a TLR agonist may  have on the disease
when used at low doses with episodic administration that would
be consistent with a vaccine adjuvant. This reiterates the previous
point about translatable data based on dosing differences, and how
this confounds the issue of relating to the clinic.
4.5. Biomarker discovery key to future AID research
While animal models are used to investigate the molecular
mechanisms of autoimmunity, the identiﬁcation of biomarkers
may  be useful in predicting and monitoring AID onset, progres-
sion, and its potential linkage to adjuvant exposure. Biomarkers
are characteristics that are objectively measured and evaluated as
indicators of normal and pathogenic biological processes [35]. One
of the goals of research on AID-linked biomarkers is to identity
markers that ﬂuctuate with homeostasis rupture, tolerance break-
ing disease development and severity, and normalize following
successful therapy [36].
A contemporary focus for AID is the role that regulatory T cells
(Tregs) play in autoimmunity, self-tolerance, immune homeosta-
sis, and suppression of immunity to pathogens/tumors. Tregs are
capable of suppressing disease. For example, when a conserved
Hsp70-epitope (B29) present in murine MHC  Class II was trans-
ferred, it induced Hsp speciﬁc CD4+ CD25+ Foxp3+ T cells and
suppressed proteoglycan-induced arthritis (PGIA) in mice [37].
Transferred cells exhibited a stable phenotype and were found in
joints and draining lymph nodes up to 2 months after transfer
[37]. Furthermore, the relationship between TLR agonists and their
ability to modulate immune function including Tregs response,
highlight the potential this subset of cells may  play in understand-
ing the role between adjuvants and autoimmunity [38].
Another area of focus in biomarker discovery resides in
micro-ribonucleic acids (microRNAs or miRNAs). They are small,
noncoding RNAs, shown to be critical regulators of host genome
expression at the post-transcriptional level. Recent developments
in diverse miRNA proﬁling may  enable the identiﬁcation of speciﬁc
miRNA as novel diagnostic and predictive markers for various dis-
eases [39]. miRNAs bind to the 3′ untranslated region (UTR) of target
messenger ribonucleic acid (mRNA) to inhibit translation or induce
1512 Conference report / Vaccine 33 (2015) 1507–1514
Table 1
Summary of TLRs that have been suggested to play a role in various autoimmune diseases in clinical and nonclinical studies reported in the literature [31–36].
Suggested involvement of TLRs in various autoimmune diseases
Diabetes SLE RA EAE/MS SjS
Human Animal Human Animal Human Animal Human Animal Human Animal
TLR1
TLR2 X X X X X X X
TLR3  X X X X X
TLR4  X X X X X X X
TLR7/8  X X X X
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MyD88  X 
RNA degradation and thereby downregulate genes. Various cells
f the innate and adaptive immune system express distinct patterns
f miRNAs and may  regulate their functions. mRNA expression
atterns are also altered in many diseases including cancer, AID,
nﬂammatory disorders, infectious diseases and allergies. More
peciﬁcally, miRNA dysregulation has been noted in SLE, rheuma-
oid arthritis, multiple sclerosis, scleroderma, etc. with expression
atterns that may  be inﬂuenced by adjuvants, and may  hold poten-
ial as highly conserved and readily accessible biomarkers for the
rogression of AID [39].
Finally, within the tetramethylpentadecane (pristane)-induced
upus murine model of SLE, lies possible biomarkers and path-
ays for future studies of AID. The model is characterized by
upus-related autoantibodies, including the production of antin-
clear antibodies, anti-dsDNA, small nuclear ribonucleic particles
snRNPs), Argonaute2/Su and ribosomal P autoantibodies and
lomerulonephritis in non-autoimmune-prone strains of mice [40].
n this pristane model, lupus-like autoimmunity is dependent on
nterferon (IFN)-g, interleukin (IL)-6 and IL-12, and is also TLR7
nd type I IFN receptor-dependent. Type I IFN has emerged as
n important pathogenic pathway in several systemic AID. How-
ver, in the pristane model, type I IFN is mainly produced by Ly6c
igh-immature monocytes, as compared with humans, where it
s produced by plasmacytoid dendritic cells [40]. Future work is,
herefore, needed to decipher the importance of not only type I IFN
ut also in the cells that produce it to help guide work as a potential
iomarker when studying AID.
.6. Potential confounding factors in assessing adjuvant and AID
inkages
Various factors are implicated in the pathogenesis of immune-
ediated diseases. Direct inﬂuences such as activation of the
nnate immune system, by infectious agents, silicone, aluminum
alts (i.e., those used as vaccine adjuvants) as well as indirect
nﬂuences such as the length of time between an adjuvant expo-
ure and before manifestation of symptoms, could all play a
ole. In recent years, four conditions: siliconosis, GWS, MMF,
nd post-vaccination adverse events have been hypothesized
y some to be related to exposure to “immune activators”. A
hared/similar complex of signs and symptoms has been given the
ame Autoimmune/inﬂammatory Syndrome Induced by Adjuvants
ASIA) [3,41,42]. While ASIA is not recognized as an ofﬁcial diagno-
is, and while there is no evidence of causality between ASIA and
accines nor adjuvants, considering timeframe after initial expo-
ure to “immune activators” could be applied as it is an important
spect to capture when assessing the scope and nature of potential
ausal factors leading to AID. When the time between an observed
ffect and exposure to a vaccine adjuvant spans the course of many
ears, this extended time period increases the variables potentially
ontributing to the onset of AID and makes it difﬁcult to link to
are events, e.g., an AID, to a speciﬁc exposure. For example, someX X
X X
studies have suggested that exposure to components of silicone
breast implants may  lead to autoimmune/ASIA-like symptoms with
a median latency period of 6 years [43], which has prompted the
FDA to request longer-term follow-up studies. These examples
highlight the importance of considering appropriate timeframes
for safety monitoring after inoculation, and emphasizes yet another
variable (time) that only further complicates the difﬁculty in deter-
mining the root cause in AID and if vaccine adjuvants can play a
role.
Genetic predisposition also contributes to the complexity of
determining a cause of AID. Narcolepsy is an immune mediated syn-
drome/AID, associated with a loss of hypocretin producing neurons
in the hypothalamus, and is rarely apparent before adolescence.
The results of the epidemiological research were shared conﬁrming
there was an increase in narcolepsy cases in the Swedish and
Finnish cohort vaccinated with Pandemrix® against H1N1 back in
2009, particularly evident in young children [44]. Of  these sub-
jects, 47 post vaccination narcolepsy subjects were analyzed and
shown to carry the narcolepsy related human leukocyte antigen
(HLA) type DQB1*0602, indicating that those affected were genet-
ically susceptible. Epidemiological data in four other EU countries
did not show the same relationship between vaccination and nar-
colepsy [45]. Adding to the complexity of the issue, the group
also looked at Canadian epidemiology data of individuals that had
received Arepanrix® (GlaxoSmithKline, Canada), which contains
H1N1 antigen produced in Canada rather than Europe, plus AS03.
The background presence of the HLA type DQB1*0602 in the Cana-
dian population is similar, albeit slightly lower at 20% compared
to 26% in Finland. The Canadian epidemiology data showed no
increase in narcolepsy and inhibition experiments of antibodies to
H1N1 viral antigens showed differences in the antigenic epitopes
between Arepanrix® and Pandemrix®. Since the workshop, other
countries have investigated whether a link between vaccination
and the onset of narcolepsy exists [44,46,47]. Some studies have
found an increased incidence of narcolepsy in adolescence upon
vaccination, and upon more in-depth analysis it appears that the
narcolepsy develops mainly in those who  possess the DQB1*0602
allele [47]. Furthermore, with a lack of an association observed
outside of European countries, a hypothesis was  proposed based
on slight differences in the antigen formulations due to manu-
facturing process. This could result in immunologically important
differences in the H1N1 antigen substance between Pandemrix®
and Arepanrix®. The hypothesis proposed was that it is not the
adjuvant per se that is responsible for the relationship, but rather
detergents (polysorbate 80) present in Pandemrix® antigen but not
in Arepanrix® that could modify the H1N1 viral antigen epitopes
and their immunogenicity, and that molecular mimicry might be
playing a role. The immunogenetic mechanism behind how these
vaccines and their various components may  have contributed to
narcolepsy remain to be determined [48], and further studies of
these differences may  be needed to determine the cause behind
this association for more informed future risk assessment.
ccine 
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. Discussion
Vaccines are one of the most successful medical breakthroughs
f modern day medicine with an extremely good safety record.
owever, the potential biological interplay between vaccine adju-
ants and a patient′s immune system has raised questions as to
hether some incidences of AID can be causally linked to adjuvant
xposures. Speciﬁcally, do some adjuvants have an intrinsic risk of
utoimmune diseases or do they just stimulate the autoimmunity
isk of certain antigens? The causes of AID are multifactorial (genet-
cs, environment, age, etc.), and may  be dependent/inﬂuenced by
he type and magnitude of immune/inﬂammation response trig-
ered under some circumstances in the host. Currently, many gaps
n knowledge still exist and future work is needed to better under-
tand and deﬁnitively address this question.
The discussions at the 2012 workshop, in synergy with the lit-
rature analysis conducted by the HESI committee, concluded that
iologically active adjuvants could in theory increase the risk of
utoimmunity by increasing the inﬂammation/immune response,
ut available pharmacovigilance and clinical databases provide no
vidence of an increased risk of autoimmunity [49]. Although the
umber of marketed adjuvants is currently limited, there is no evi-
ence as to whether a speciﬁc type of adjuvant would increase the
isk of an AID.
Confounding aspects of potential genetic predisposition, as in
he case of the Pandemrix®/narcolepsy data as well as variation
n biological mechanism of action of adjuvants add to the com-
lexity of this issue. Adjuvants are varied in their modus operandi,
nd/or physical properties, e.g., oil-based adjuvants, which act as
 local depot, versus speciﬁc immunomodulators that target spe-
iﬁc TLRs. Improved characterization of whether a speciﬁc adjuvant
riggers a “broad immune reaction” or more restricted and deﬁned
athways would aid in assessing biological mechanisms that could
e causally linked to AID. Enhanced understanding of the native
mmune system function in reaction to speciﬁc adjuvant exposures,
ifferences in mode of action, potency, dose relationships, models,
outes, and temporality remain available opportunities to improve
asic knowledge in this ﬁeld. In addition to nonclinical studies, tar-
eted post market analysis could assist in identifying potentially
elevant mechanistic pathways or patient populations most at risk
f AID.
From a regulatory perspective, it would be helpful to build con-
ensus on key risk biological factors of AID and incorporate those
nto scientiﬁc justiﬁcation for regulatory approval or dismissal of
 vaccine. Examples of targeted risk management approaches in
rug development include the use of a high throughput screening
pproach to select adjuvants targeting speciﬁc molecules that do
ot induce systemic activation and have a short half-life, or the
election of adjuvants known to be local acting and transient.
Available post-marketing data continues to show adjuvants
ave a good safety proﬁle. New initiatives such as the IMI  BIOVAC-
AFE project have been recently established to collect additional
ost-market data and scientiﬁc understanding related to the safety
f vaccination. This program aims to contribute to the current
nowledge base through clinical trials to deﬁne biomarkers, gener-
tion of databases and guidelines, etc. It is critical to remember that
ny potential relationships between vaccination and rare/very rare
dverse events in humans can only be detected in large epidemio-
ogical studies following vaccination. However, even in large scale
tudies, the potential for multiple confounders and exposures over
n extended temporal period make it challenging to scientiﬁcally
stablish causal linkages. While only one piece of a much larger puz-
le, epidemiological data may  help guide more sound decision mak-
ng processes regarding vaccines by both researchers and indirectly
y the general public. Along with routine post marketing phar-
acovigilance of vaccines, large scale epidemiological studies may33 (2015) 1507–1514 1513
enhance the ability to adjust risk/beneﬁt assessments to account for
regional differences in disease epidemiology and associated mor-
bidity/mortality, as well as differences in genetics, diet, nutrition,
parasite burden, natural background rates of AID, etc. [50].
6. Conclusions
Autoimmune diseases are complex and multi-factorial disor-
ders, and changes in autoreactive T and/or B cells homeostasis
contribute to the development of autoimmunity. Such changes
could, in theory, be induced by non-adjuvanted vaccines but might
be even more frequent and plausible with adjuvanted vaccines;
therefore, studying autoimmunity risk is important to be consid-
ered in the development of adjuvants. So far, there is no compelling
clinical evidence that adjuvants are causally related to any autoim-
mune phenomena.
In animals, adjuvants (e.g., IFA and CFA), or components of adju-
vants (e.g., oils) are being used to induce autoimmunity disease
models in combination with auto-antigens or based on genetic sen-
sitivity. The animal models used in autoimmunity research are not
adequate to be used for risk assessment for potential AID for new
adjuvanted vaccines in this respect. As shown above, there is no
evidence of a link between adjuvanted vaccines and AID so far,
but considering there are so many contributing factors in AID, it is
challenging and complex to completely rule out a theoretical risk.
The future should focus on understanding the mode of action of
adjuvants and mechanistic pathways of AID, which together may
provide future biomarkers related to autoimmune diseases that
may  help provide better understanding and risk management.
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